not tagged
NeoGenomics Pharma
['melanoma', 'marker ']
we're pleased to attend the esmo congress 2022. the neogenomics pharma services division is presenting a poster titled, "pak4 as a potential marker for poor response to immunotherapy in melanoma patients." to read about the results and more, visit us at #esmo22 at booth # 420. 
One Lab.  Vital Answers.